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Abstract
Background Chronic inﬂammation, changes in body composition, and declining physical function are hallmarks of the ageing
process. The aim of the present study was to provide a preliminary characterisation of the relationship among these age-
related phenomena via multivariate modelling.
Methods Thirty-ﬁve old adults (OAs) and 17 young adults (YAs) were enrolled. The volume of skeletal muscle, subcu-
taneous adipose tissue (SAT), and intermuscular adipose tissue (IMAT) of the thigh was quantiﬁed by three-dimensional
magnetic resonance imaging. Muscle strength was measured by knee extension strength testing. In OAs, physical perfor-
mance was further assessed via the Short Physical Performance Battery (SPPB). Multi-block partial least squares-
discriminant analysis (PLS-DA) was employed to explore the relationship among inﬂammatory proﬁles and functional
and imaging parameters. Double cross-validation procedures were used to validate the predictive ability of the PLS-
DA model.
Results The optimal complexity of the PLS-DA model was found to be two latent variables. The proportion of correct
classiﬁcation was 92.3% in calibration (94.1% in YAs and 91.4% in OAs), 84.6% in internal validation (95.3% in YAs and
78.5% in OAs), and 82.6% in external validation (94% in YAs and 76.9% in OAs). Relative to YAs, OAs were characterised
by smaller muscle volume, greater IMAT volume, lower muscle strength, and higher levels of myeloperoxidase,
P-selectin, soluble intercellular adhesion molecule 1, and vascular cell adhesion molecule 1. Compared with OAs with
SPPB >8, those scoring ≤8 were characterised by smaller muscle volume, greater SAT volume, lower muscle strength,
and higher levels of interleukin 1 beta, 6, 10, 12, 13, tumour necrosis factor alpha, and granulocyte-macrophage
colony-stimulating factor.
Conclusions Multi-block PLS-DA identiﬁed distinct patterns of relationships among circulating cytokines and functional and
imaging parameters in persons of different ages and varying levels of physical performance. The longitudinal implementation
of such an innovative strategy could allow for the tracking of health status over time, the early detection of deviations in
health trajectories, and the monitoring of response to treatments.
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Introduction
Chronic low-grade inﬂammation, changes in body composi-
tion, and declining physical performance are three intercon-
nected phenomena that characterise the ageing process.1–3
The ‘perfect storm’ triggered by such a triad eventually leads
to adverse health outcomes, including disability, the loss of in-
dependence, morbidity, and mortality.4
The association between inﬂammation and body composi-
tion changes as well as physical function impairment has
been known for many years.5–7 Yet, no ‘gold standard’ inﬂam-
matory biomarker has been identiﬁed that is consistently as-
sociated with adverse outcomes in older adults.8 Indeed, the
effects of inﬂammation on health status have been inferred
mostly through the analysis of single biomarkers. However,
these mediators act in a complex and coordinated network
involving multiple feedback mechanisms through which the
function of individual factors may be modiﬁed, replaced, or
modulated by others. Nevertheless, only a handful of studies
have attempted to develop a comprehensive appraisal of in-
ﬂammatory markers in relation to adverse health-related
events in older adults.3,7,9–12
Notably, although muscle mass is an important determi-
nant of muscle strength and physical function, a substantial
divergence has been reported between changes in muscle
quantity and function over the course of ageing.13 Indeed,
the annual decline in lower extremity strength is approxi-
mately three-fold greater than the loss of lean mass.14 Re-
markably, maintaining or even gaining muscle mass does
not protect against declines in muscle strength during age-
ing.14 These observations indicate that, in addition to muscle
quantity, the quality of the remaining tissue impacts force
production in advanced age.14 For instance, qualitative alter-
ations of muscle composition may disrupt tissue architecture
and promote chronic local inﬂammation, which may further
deteriorate muscle performance.15,16
In order to capture the complex interrelation linking
humoral, functional, and body compositional factors during
ageing, a new analytical approach is needed that moves from
the study of single parameters to the development of
multivariate/multidimensional modelling of a panel of com-
plementary processes.17 The present study was therefore
undertaken to provide a preliminary characterisation of the
relationship linking systemic inﬂammation, body composi-
tion, and physical function in old age. To address this re-
search question, an array of inﬂammatory mediators was
assayed in blood samples of community-living young and
old persons. Three-dimensional magnetic resonance imaging
(3D-MRI) was used to determine the tissue composition of
the thigh. Muscle strength and function of the lower extrem-
ities were assessed through standard tests. Multivariate
statistical models were constructed to explore the complex,
multidirectional connections relating systemic inﬂammation,
thigh tissue composition, and physical function.
Materials and methods
Participants
Sedentary young (18–35 years) and old (>70 years)
community-living persons were enrolled under the coordina-
tion of the Recruitment Core of the University of Florida’s
Claude D. Pepper Older Americans Independence Centre. Re-
cruitment strategies included media articles, direct mailings,
newspaper announcements, and presentations to community
groups. Following telephone interview, eligible persons were
invited to attend a screening visit during which the purpose
and procedures of the study were explained and informed
consent was obtained.
A set of eligibility criteria was elaborated to minimise the
possible confounding effects of co-morbid conditions, medi-
cations, or lifestyle habits on the relationship among inﬂam-
mation, body composition, and physical performance.1
Other selection criteria were utilised to ensure that candi-
date participants would understand the purpose of the in-
vestigation and comply with the study procedures.1 The
presence of any of the following characteristics was consid-
ered exclusionary: smoking in the prior 12months; engage-
ment in regular physical exercise (i.e. any kind of
structured physical activity performed for more than
20min per week in the previous two months); history of
recreational drug use or alcohol abuse; active treatment
for cancer or cancer in the past three years; heart failure
New York Heart Association class III or IV; stroke with upper
and/or lower extremity involvement; Parkinson’s disease or
other neurological disorders likely to interfere with physical
function; major psychiatric illnesses; peripheral vascular
disease Lériche-Fontaine stage 3 or 4; history of
life-threatening cardiac arrhythmias; cognitive impairment
(i.e. Mini Mental State Examination score ≤21); renal disease
requiring dialysis; lung disease requiring chronic steroids;
chronic viral diseases (e.g. hepatitis B and C, HIV); lower
extremity amputation; severe knee or hip osteoarthritis
limiting mobility; diabetes with visual, vascular, or
neuropathic complications; inﬂammatory diseases (e.g.
rheumatoid arthritis, vasculitis, autoimmune disorders, in-
ﬂammatory bowel disease); use of growth hormone,
oestrogen replacement, testosterone, steroids, or non-
steroidal anti-inﬂammatory drugs on a regular basis; severe
obesity [i.e. body mass index (BMI) ≥35]; being underweight
(i.e. BMI ≤18.5); active weight loss >5 kg in prior three
months; life-threatening illnesses with an estimated life
expectancy <1 year. Persons on statin treatment were asked
to refrain from drug administration one month prior to
blood draw upon their general practitioner’s approval.
Eligible persons were excluded if they had contraindications to
the acquisition of MRI (e.g. claustrophobia, heart pacemaker/
deﬁbrillator, metallic stents, aneurysm clips, metal implants or
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prosthesis, neurostimulation systems, insulin pumps, or other
infusion pumps). The study protocol was approved by the
University of Florida’s Institutional Review Board and all
participants provided written informed consent before
enrolment.
Three-dimensional magnetic resonance imaging
for thigh composition analysis
T1-weighted MRI was employed to analyse the tissue compo-
sition of the thigh of the dominant side. Images were ob-
tained using a 3.0-tesla magnet (Philips Medical Systems,
Bothell,WA), as detailed elsewhere.18 Muscle tissue, subcuta-
neous adipose tissue (SAT), and intermuscular adipose tissue
(IMAT) were quantiﬁed volumetrically, as described by
Buford et al.1 Images were analysed using the freely available
software package MIPAV 1.3 (Medical Image Processing,
Analysis and Visualization; Center for Information Technol-
ogy, National Institutes of Health, Bethesda, MD; http://
mipav.cit.nih.gov).
Assessment of muscle strength and physical
function
In all participants, muscle strength was assessed via knee ex-
tension strength testing. The test was set up to measure the
maximal concentric isokinetic strength of knee extensors of
the dominant side.18 Brieﬂy, participants were asked to exert
their maximum force while extending the knee from 90° to 0°
of ﬂexion at 60° per second with a hip angle of 90–100°. The
maximal peak torque achieved out of three test repetitions
(Nm) was used for the analysis.
In older participants, physical function was further
assessed through the Short Physical Performance Battery
(SPPB).19 The SPPB is composed of three timed subtests that
evaluate standing balance, usual gait speed, and the ability to
rise from a chair. For the standing balance test, participants
were asked to stand in three increasingly challenging posi-
tions for 10 s each: standing with feet in side-by-side,
semi-tandem, and full tandem positions. For the gait speed
subtest, participants were asked to walk at their usual pace
along a 4m course, starting from a standing still position.
The faster of two trials (ms1) was used for the calculation
of the summary score. Finally, for the chair-stand subtest,
participants were asked to rise from a chair and sit down ﬁve
times as quickly as possible with arms folded across the
chest. Each of the three SPPB subtasks was categorised into
a ﬁve-level score according to predeﬁned cut-points,19 with
0 representing inability to do the test and 4 corresponding
to the highest level of performance.
Multiplexed immunoassay for the quantiﬁcation of
inﬂammatory markers
A panel of 14 inﬂammatory markers, growth factors, and vas-
cular adhesion molecules, related to systemic and/or vascular
inﬂammation, was measured via a multiplex, magnetic
bead-based immunoassay (MILLIPLEX® MAP; EMD Millipore,
Billerica, MA), as detailed elsewhere.3 Brieﬂy, analytes were
assayed in the serum by the MILLIPLEX® MAP High Sensitivity
Human Cytokine Kit Multiplex Assay (Cat. # HSCYTMAG-60SK)
and in the plasma by the MILLIPLEX® MAP Human Cardiovas-
cular Disease Magnetic Bead Panel 2—Cardiovascular Disease
Multiplex Assay (Cat. # HCVD2MAG-67K). The multiplex im-
munoassay panels were analysed on a MILLIPLEX® Analyzer
3.1 xPONENT System (Luminex® 200™), and data analysis
was performed through the MILLIPLEX® Analyst software.
The inter-assay coefﬁcients of variation were <5% for the
High Sensitivity Human Cytokine Kit Multiplex Assay and
<15% for the Cardiovascular Disease Multiplex Assay.
Statistical analysis
All analyses were performed using in-house routines running
under Matlab R2012b environment (The MathWorks, Natick,
MA). Differences in demographic, anthropometric, clinical,
functional, and body composition characteristics between
the experimental groups were assessed via the Mann–
Whitney U test and χ2 test, for continuous and categorical
variables, respectively. Both tests were two-sided, with statis-
tical signiﬁcance set at P< 0.05.
To explore the relationship among inﬂammation, thigh
composition, and physical function, a classiﬁcation approach
based on multi-block partial least squares-discriminant
analysis (PLS-DA) was adopted. PLS-DA is the classiﬁcation
analogue of PLS regression, a method that builds the linear
relation between a set of responses Y and a matrix of predic-
tors X by projecting the latter onto a low-dimensional space
of latent (abstract) variables (LVs). LVs are characterised by
having the highest covariance with the responses to be
predicted. In order for the method to also be used in classiﬁ-
cation where the responses to be predicted are of a qualita-
tive and not quantitative nature (in the present study,
whether the participant is young or old), y is coded as a
‘dummy’ binary vector, assuming the value 1 if the partici-
pant is old and 0 if he/she is young. The classiﬁcation of the
individuals is then operated on the basis of the predicted
value of y, adopting a threshold value of 0.5. If the predicted
y is above that value, the individual is classiﬁed as old, while if
it is below, he/she is predicted to be young.
In particular, in the present investigation, because the set
of predictors originated from different experimental domains
(i.e. blood biochemistry, imaging, and physical function), a
multi-block approach was adopted to fuse the information
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obtained from the physical performance/imaging tests and
the multiplexed assay, in order to interpret the relationship
between them. In multi-block PLS-DA, the two data matrices
containing the blocks of predictors (Xblock1 and Xblock2) are
concatenated after a pre-processing stage called block-scaling
(each matrix is divided by its variance, so that the two blocks
contribute equally to the model) to form a single matrix Xmb:
Xmb ¼ Xblock1Xblock2½ :
Xmb has as many rows as the number of individuals and as
many columns as the sum of the variables in the two blocks.
A PLS-DA model is then built using the matrix Xmb as the pre-
dictors and the dummy vector containing the class informa-
tion as the response.
The statistical reliability of the PLS-DA model was subse-
quently veriﬁed by a double cross-validation procedure and
by means of randomisation tests. The double cross-validation
is a variant of standard cross-validation and includes an outer
and an inner loop. The ﬁrst loop mimics an external test set
to be used for the validation of a PLS-DA model the optimal
complexity of which is chosen on the basis of the error in
the inner loop samples. The randomisation test is used to ob-
tain a non-parametric distribution of the ﬁgures of merit of
the PLS-DA model under the null hypothesis to assess its sta-
tistical signiﬁcance. Three ﬁgures of merit were considered in
the present study: (i) the number of misclassiﬁcations (NMC);
(ii) the area under the receiver operating characteristic (ROC)
curve (AUROC); and (iii) the value of the discriminant Q2
(DQ2). NMC corresponds to the number of classiﬁcation
errors that occurred between the age groups (young vs.
old). AUROC is a measure of a test’s discriminatory power.
Its values range between 1 (perfect classiﬁcation) and 0 (no
discrimination). DQ2 is a modiﬁcation of the standard Q2
and was introduced to cope with the peculiarities of classiﬁ-
cation problems addressed by regression methods.20 DQ2 is
especially suitable for discriminating between groups in
which the biological responses can be subtle and highly
variable among the individuals. As its regression analogue,
DQ2 assumes its highest values in the case of a perfect
discrimination between classes. Different from standard Q2,
DQ2 is not bound to the 0–1 range of values (i.e. it can also
be negative).
Results
Descriptive characteristics of the study population
A total of 52 participants were recruited for the study, 17
young adults (YAs) and 35 older adults (OAs). Demographic,
anthropometric, and functional characteristics, and thigh
composition of the participants by age group are listed in
Table 1. Relative to the YA group, OAs showed higher BMI
and lower knee extensor strength. The thigh composition of
OA participants was characterised by smaller muscle and
SAT volumes, and greater IMAT volume compared with YAs.
No differences between groups were observed with regard
to gender or ethnicity distribution. The median concentra-
tions of circulating inﬂammatory markers in the two age
groups are reported in Table 2.
Integration of inﬂammatory, functional, and
imaging parameters via multi-block partial least
squares-discriminant analysis
To proceed with the multi-block PLS-DA analysis, data ob-
tained from multiplexed assay, 3D-MRI, and functional tests
were arranged in two matrices of dimension 52 × 14 and
52 × 4, respectively. Each matrix was ﬁrst auto-scaled and
then block-scaled prior to be concatenated in the ﬁnal
52 × 18 matrix Xmb to be used in the multi-block PLS-DA
modelling. To explore the relationship among systemic in-
ﬂammation, thigh composition, and physical performance,
Xmb was employed as the predictor matrix to build a classiﬁ-
cation model for the discrimination between YA and OA
participants. The optimal complexity of the model as well as
the validation of its predictive ability was assessed by means
of a double cross-validation procedure, coupled with
randomisation tests. Twenty runs of double cross-validation
with six cancellation groups in the outer loop and ﬁve in
the inner loop were carried out and the results compared
with those of randomisation tests with 1000 permutations
performed under the same conditions (Figure 1). The double
cross-validation procedure provided information on both the
model complexity and its reliability. In all iterations, the
optimal model complexity was two LVs, which were then
considered to build the ﬁnal model.
As shown in Figure 1, the differences in cytokine, thigh
composition, and physical performance proﬁles between age
groups were statistically signiﬁcant. Indeed, an average NMC
of 4 was found in calibration, with 92.3% correct
classiﬁcation (94.1% in YAs and 91.4% in OAs). In the
internal validation set, correct classiﬁcation was achieved in
84.6% of study participants (95.3% in YAs and 78.5% in OAs).
Finally, in the external validation set, the proportion of correct
classiﬁcation was 82.6% (94% in YAs and 76.9% in OAs). In Fig-
ure 1a, NMC in external validation is compared with its distri-
bution under the null hypothesis. The NMC value obtained on
the real dataset fell outside of the corresponding null hypoth-
esis distribution, indicating that the proﬁles of YAs were
signiﬁcantly different from those of OAs (P< 0.05). These
results are conﬁrmed by the inspection of AUROC (Figure
1b) and DQ2 plots (Figure 1c).
To explore the relationship between inﬂammatory media-
tors and functional and imaging parameters, scores and load-
ings plots for the two signiﬁcant LVs in the optimal model
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were considered. The scores plot, which describes the coordi-
nates of the participants onto the space spanned by the LVs,
is depicted in Figure 2a. The plot shows that the separation
between YA and OA participants occurs along a direction that
passes approximately through the ﬁrst and third quadrant of
the graph. By comparing this ﬁnding with the loadings plot
(Figure 2b), which describes the importance of the experi-
mental variables in determining the projection (i.e. in the
construction of the LVs), it is possible to interpret this differ-
ence in terms of the observed predictors. In particular, a sys-
tematic relation between greater SAT and lower IMAT
volumes is evident, with higher values of IMAT being corre-
lated with increased concentrations of P-selectin,
myeloperoxidase (MPO), soluble intercellular adhesion mole-
cule 1 (sICAM-1), and vascular cell adhesion molecule 1
(sVCAM-1). The scores plot further indicates that higher
concentrations of those four cytokines and greater IMAT vol-
umes (and correspondingly smaller SAT volume) differentiate
OA from YA participants. Moreover, lower muscle volume
and knee extensor strength are correlated with higher con-
centrations of a group of inﬂammatory cytokines [interleukin
(IL) 1 beta, IL6, IL10, IL12, IL13, tumour necrosis factor alpha
(TNF-α), and granulocyte-macrophage colony-stimulating fac-
tor (GM-CSF)], which also appear to be highly related to one
another.
Finally, even though OAs were analysed as a single group,
the PLS-DA model was able to separate those with SPPB >8
(‘high-functioning’; n = 21) from participants scoring ≤8
(‘low-functioning’; n = 14) (Figure 3). ‘Low-functioning’ OAs
were characterised by lower muscle volume and knee exten-
sor strength and correspondingly higher concentrations of
IL1beta, IL6, IL10, IL12, IL13, TNF-α, and GM-CSF.
Table 2 Median concentrations of circulating inﬂammatory biomarkers according to the age group
Young adults (n=17) Median (IQR) Older adults (n=35) Median (IQR)
GM-CSF, pgmL1 * 1.02 (0.11–3.71) 0.32 (0.09–2.49)
IFN-γ, pgmL1 * 1.83 (0.35–12.43) 0.46 (0.09–8.19)
IL1β, pgmL1 * 0.28 (0.08–0.62) 0.13 (0.06–0.56)
IL5, pgmL1 * 0.10 (0.05–0.35) 0.20 (0.09–1.00)
IL6, pgmL1 * 0.83 (0.35–1.52) 2.01 (0.81–5.23)
IL8, pgmL1 * 3.06 (2.58–3.65) 3.59 (2.83–5.60)
IL10, pgmL1 * 15.59 (9.70–27.30) 18.86 (15.28–33.60)
IL12(p70), pgmL1 * 2.27 (0.05–6.40) 0.68 (0.05–3.60)
IL13, pgmL1 * 0.66 (0.15–1.99) 0.89 (0.10–4.48)
TNF-α, pgmL1 * 6.06 (4.34–8.53) 7.57 (4.35–11.29)
MPO, ngmL1 ¥ 21.39 (16.81–34.56) 22.34 (16.59–34.78)
P-selectin, ngmL1 ¥ 32.63 (19.95–46.24) 43.05 (30.24–51.95)
sICAM-1, ngmL1 ¥ 56.72 (39.24–77.99) 67.67 (49.56–87.92)




GM-CSF: granulocyte macrophage colony-stimulating factor; IFN-γ: interferon gamma; IL: interleukin; MPO: myeloperoxidase;
sICAM-1; soluble intercellular adhesion molecule 1; sVCAM-1: soluble vascular cell adhesion molecule 1; TNF-α: tumour necrosis
factor alpha.
Table 1 Descriptive characteristics of the study sample according to the age group
Young adults (n=17) Older adults (n=35) P
Age, years (mean± SD) 23.4±3.9 78.1±5.9 <0.0001
Gender (female), n (%) 8 (47.1) 16 (45.7) 0.8376
Ethnicity (Caucasian), n (%) 15 (88.2) 35 (100) 0.1933
BMI, kg/m2 (mean± SD) 24.1±4.9 27.4±4.1 0.0153
Number of disease conditions* (mean± SD) 0.2± 0.4 1.3±1.2 <0.0001
Number of medications (mean± SD) 2.1± 2.7 3.3±3.0 0.07
Peak torque extension, Nm (mean± SD) 173.2±38.4 110.2±42.0 <0.0001
SPPB (mean± SD) — 9.2±3.00 —
Thigh muscle volume, cm3 (mean± SD) 563.3±121.8 407.6±127.6 0.0001
Thigh IMAT volume, cm3 (mean± SD) 88.4±20.9 115.3±28.5 0.0012
Thigh SAT volume, cm3 (mean± SD) 447.4±262.6 325.1±155.4 0.0399
*Includes hypertension, coronary artery disease, prior stroke, peripheral vascular disease, diabetes, chronic obstructive pulmonary disease,
and osteoarthritis.
BMI: body mass index; IMAT: intermuscular adipose tissue; SAT: subcutaneous adipose tissue; SD: standard deviation; SPPB: Short Physical
Performance Battery.
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Discussion
In recent years, chronic systemic inﬂammation, changes in
body composition, and declining physical performance have
been among the most actively investigated topics in
biogerontology. Indeed, each of them is intrinsic to the age-
ing process and is linked to a wide range of adverse health
outcomes.21 Although inﬂammation, body composition dete-
rioration, and functional impairment are intimately intercon-
nected, the literature is devoid of investigations that have
examined the relationship linking those three hallmarks of
ageing. Indeed, depending on the study design, one of these
phenomena was typically considered as a confounding factor
in the analysis of the other two components.
In this exploratory study, an innovative analytical approach
based on multi-block PLS-DA was adopted to capture poten-
tially relevant information that could otherwise remain
concealed using traditional statistical methods. The most no-
ticeable ﬁndings were the negative relation, determined both
in YA and OA participants, between SAT and IMAT volumes,
and the positive correlation of IMAT with circulating levels
of P-selectin, MPO, sVCAM-1, and sICAM-1 (Figure 2b). This
latter ﬁnding, while corroborating previous observations of
increasing fat deposition in aged muscle,22 adds interesting
cues on the systemic inﬂammatory milieu in which the age-
related changes in body composition occur. IMAT depots, be-
sides disrupting myoﬁbre orientation and, hence, force gen-
eration, can release several inﬂammatory mediators.22
These, in turn, may contribute to local and systemic inﬂam-
mation23 as well as to muscle dysfunction.24 On the other
hand, chronic systemic inﬂammation promotes ectopic lipid
deposition in non-adipose tissues, including muscle.18 Our
ﬁndings together with those of previous investigations sug-
gest that a self-reinforcing mechanism could take place with
advancing age, through which inﬂammation and alterations
of body composition contribute to physical function
impairment.
Although the study was not designed to address mechanis-
tic hypotheses, it may be speculated that the relationship be-
tween IMAT and a speciﬁc cluster of inﬂammatory cytokines
could reﬂect the involvement of endothelial activation in
age-related muscle remodelling. Indeed, P-selectin, sICAM-
1, and sVCAM-1 are all released by activated endothelial
cells.24 MPO, on the other hand, contributes to endothelial
Figure 2 Scores (a) and loadings (b) plots showing the relationships among inﬂammatory, functional, and thigh composition parameters in the space
spanned by the two latent variables (LV1 and LV2), as determined by multi-block PLS-DA. In the scores plot, the diagonal line and the double-headed
arrow (added to facilitate interpretation) indicate the boundary between age groups and the direction along which the separation occurs, respectively.
The loadings plot shows a negative correlation between subcutaneous fat (SubFat) and intermuscular adipose tissue (IMAT) volumes, and a positive
correlation between IMAT volume and circulating levels of P-selectin, MPO, sVCAM-1, and sICAM-1.
Figure 1 Distribution of (a) number of misclassiﬁcations (NMC), (b) area under the receiver operating characteristic (ROC) curve (AUROC), and (c) dis-
criminant Q2 (DQ2) values under their respective null hypothesis as estimated by permutation tests with 1000 randomisation (blue histograms) and the
corresponding values obtained by the PLS-DA model on unpermuted data (red circles).
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dysfunction through several mechanisms, involving oxidative
and nitrosative damage, nitric oxide catabolism, NADPH con-
sumption, and complement-dependent cytotoxicity.25
Considerable variability in biomarker concentrations was
observed within and between age groups; notwithstanding,
consistent patterns were detected. In OA participants,
circulating levels of a set of pro- and anti-inﬂammatory
mediators (i.e. IL1beta, IL6, IL10, IL12, IL13, TNF-α, and GM-
CSF) were found to be higher than in YAs. This cluster of cy-
tokines, which were highly correlated with one another, was
inversely correlated with muscle volume and knee extensor
strength (Figure 2b). This ﬁnding is consistent with a recent
report by Petersen et al.7 who described similar age-
dependent patterns of relationships between inﬂammatory
mediators and physical performance measures. Moreover, a
signiﬁcant association between higher circulating levels of
both pro- and anti-inﬂammatory cytokines (including IL6,
IL10, and TNF-α) and SPPB scores has recently been reported
in older Chinese persons with various degrees of disability.12
While a chronic increase in circulating levels of pro-
inﬂammatory mediators is a well-recognised age-related phe-
nomenon,4 the co-occurrence of higher levels of IL10 and
IL13 and their inverse relation with muscle volume and
strength represent novel ﬁndings. Besides their well-known
role in attenuating monocyte/macrophage function,26 IL10
and IL13 may also inﬂuence muscle trophism, regeneration,
and metabolism.27–29 Thus, our ﬁndings suggest the existence
of a generalised perturbation in the cytokine network, which
could impact muscle health. Further studies are needed to
fully dissect such processes, with the prospect of targeting
inﬂammatory pathways to maintain or restore muscle mass
and function in old age.
Remarkably, by inspecting the scores and prediction plots
of the PLS-DA model (Figure 3), a separation can be appreci-
ated between ‘low-’and ‘high-functioning’ OA participants.
Speciﬁcally, ‘high-functioning’ individuals show a proﬁle of
inﬂammatory, thigh composition, and muscle strength
indices intermediate between YAs and ‘low-functioning’ par-
ticipants. It is worth noting that that the proﬁle of approxi-
mately one third of ‘high-functioning’ OAs is overlapping
with that of YAs. The relationship pattern is not attributable
to differences in age or co-morbidity burden, which were
similar in the two OA groups (data not shown). This ﬁnding
supports the idea that, in older persons, functional status is
intimately linked with inﬂammatory and muscle-speciﬁc pa-
rameters. The longitudinal analysis of these proﬁles through
multi-block PLS-DA models may allow the health status of
an older person to be tracked over time, in order to timely
identify possible deviations from the successful ageing
trajectory.17
Although reporting novel ﬁndings, our study presents
some limitations that need to be acknowledged. First, analy-
ses were conducted in a relatively small group of participants
and involved a vast array of experimental variables. However,
the PLS-DA approach is particularly suited for such an exper-
imental design because it allows analysing matrices in which
(i) the number of variables is larger than the number of indi-
viduals; (ii) the variables are correlated with each other; and
(iii) the differences in biological parameters could be subtle
and highly variable among the individuals.30 Moreover, the
double cross-validation procedure conﬁrmed the reliability
of the PLS-DA model,20,31 which adds value to our ﬁndings.
Yet, because of the limited sample size, analyses could not
be adjusted for possible confounders. Eligibility criteria were
purposely restrictive to minimise the chances that the
relationship among inﬂammation, thigh composition, and
functional status would be confounded by disease conditions,
medications, or lifestyle habits. At the same time, this choice
does not allow for the results to be extended to severely ill,
multimorbid older persons. In addition, the study sample
was mostly comprised of Caucasian individuals, which im-
pedes generalising the ﬁndings to other ethnic groups. Al-
though enrolees were not engaged in structured physical
exercise, the amount of physical activity was not objectively
quantiﬁed. Therefore, the relationship between the variables
analysed and the overall level of physical activity could not be
established. The lack of information on food intake prevented
the possible inﬂuence of diet on the variables of interest to
be explored. The cross-sectional design of the study does
not allow inference to be drawn on the time course of
changes of the variables considered. Finally, although a large
number of inﬂammatory markers were assayed, not all
known mediators could be considered. Notably, C-reactive
protein, one of the most popular inﬂammatory markers,
Figure 3 Scores plot showing the separation of participants according to
inﬂammatory, functional, and thigh composition parameters in the space
spanned by the two latent variables (LV1 and LV2), as determined by
multi-block PLS-DA. The diagonal line (added to facilitate interpretation)
corresponds to the boundary between older adults with SPPB >8 (‘high-
functioning’) and those with SPPB ≤8 (‘low-functioning’). The double-
headed arrow indicates the direction along which the separation occurs.
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was not measurable with the multiplex assay kits employed
in the present study.
In conclusion, multi-block PLS-DA revealed distinct pat-
terns of relationships among circulating cytokines and func-
tional and imaging parameters in persons of different ages
and varying levels of physical performance. As opposed to
conventional monodimensional approaches, the simulta-
neous evaluation of multiple factors belonging to different
domains may be better suited to cope with the heterogeneity
of complex age-related phenomena.17 Indeed, the longitudi-
nal implementation of such an innovative strategy could al-
low for the tracking of health status over time, the early
detection of deviations in health trajectories, and the moni-
toring of response to treatments. Longitudinal analyses could
also help simplify the proposed approach by identifying
which variable or set of parameters shows the best ability
to predict relevant health outcomes in late life, for future ap-
plication in the clinical arena. Eventually, this knowledge
would assist in developing more comprehensive and
patient-tailored interventions.32,33
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